First-in-human Study of Anticancer Immunotherapy Drug Candidate Mobilan: Safety, Pharmacokinetics and Pharmacodynamics in Prostate Cancer Patients

Overview

Journal Oncotarget

Specialty Oncology

Date 2020 Apr 16

PMID 32292576

Citations 6

Authors

Natalia V Eremina

Vasily I Kazey

Sergey V Mishugin

Roman V Leonenkov

Dmitry Y Pushkar

Vadim L Mett

Andrei V Gudkov

Affiliations

Soon will be listed here.

Abstract

Toll-like receptor 5 (TLR5) controls endogenous immune responses to pathogens and is a promising target for pharmacological stimulation of anti-tumor immunity. Mobilan is an innovative gene therapy agent consisting of a non-replicating bicistronic adenovirus directing constitutive expression of human Toll-like receptor 5 (TLR5) and the secreted flagellin-based TLR5 agonist, 502s. In mice, Mobilan injection into prostate tumors resulted in autocrine TLR5 signaling, immune system activation, and suppression of tumor growth and metastasis. Here we report a first-in-human placebo-controlled clinical study of Mobilan aimed at evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of a single intra-prostate injection of Mobilan in early stage prostate cancer patients. Mobilan was safe and well-tolerated at all tested doses; thus, the maximum tolerated dose was not identified. Injection of Mobilan induced signs of self-resolving inflammation not present in placebo-injected patients, including transient elevation of PSA and cytokine (G-CSF, IL-6) levels, and increased lymphoid infiltration in prostate tissue. The highest dose of Mobilan (10 viral particles) produced the best combination of safety and pharmacodynamic effects. Therefore, Mobilan is well-tolerated and induces the expected pharmacodynamic response in humans. These results support further clinical development of Mobilan as a novel immunotherapy for prostate cancer.

Citing Articles

Clinical landscape of macrophage-reprogramming cancer immunotherapies.

Rannikko J, Hollmen M Br J Cancer. 2024; 131(4):627-640.

PMID: 38831013 PMC: 11333586. DOI: 10.1038/s41416-024-02715-6.

The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer.

Wang X, Qiu W, Liu H, He M, He W, Li Z Cancer Biol Med. 2023; 20(9).

PMID: 37731205 PMC: 10546094. DOI: 10.20892/j.issn.2095-3941.2023.0033.

Toll-like receptor-targeted anti-tumor therapies: Advances and challenges.

Yang Y, Li H, Fotopoulou C, Cunnea P, Zhao X Front Immunol. 2022; 13:1049340.

PMID: 36479129 PMC: 9721395. DOI: 10.3389/fimmu.2022.1049340.

The Role of Toll-like Receptors (TLRs) Mediated Inflammation in Pancreatic Cancer Pathophysiology.

Orlacchio A, Mazzone P Int J Mol Sci. 2021; 22(23).

PMID: 34884547 PMC: 8657588. DOI: 10.3390/ijms222312743.

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma.

Rohatgi A, Kirkwood J Front Oncol. 2021; 11:640314.

PMID: 33732652 PMC: 7958874. DOI: 10.3389/fonc.2021.640314.

References

Klemann N, Roder M, Helgstrand J, Brasso K, Toft B, Vainer B . Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study. Lancet Oncol. 2017; 18(2):221-229. DOI: 10.1016/S1470-2045(17)30025-6. View

Bill-Axelson A, Holmberg L, Garmo H, Rider J, Taari K, Busch C . Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014; 370(10):932-42. PMC: 4118145. DOI: 10.1056/NEJMoa1311593. View

Rangel-Sosa M, Aguilar-Cordova E, Rojas-Martinez A . Immunotherapy and gene therapy as novel treatments for cancer. Colomb Med (Cali). 2017; 48(3):138-147. PMC: 5687866. DOI: 10.25100/cm.v48i3.2997. View

Mett V, Komarova E, Greene K, Bespalov I, Brackett C, Gillard B . Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy. Oncogene. 2017; 37(4):439-449. PMC: 5799711. DOI: 10.1038/onc.2017.346. View

Fountzilas C, Patel S, Mahalingam D . Review: Oncolytic virotherapy, updates and future directions. Oncotarget. 2017; 8(60):102617-102639. PMC: 5731986. DOI: 10.18632/oncotarget.18309. View

Hajam I, Dar P, Shahnawaz I, Jaume J, Lee J . Bacterial flagellin-a potent immunomodulatory agent. Exp Mol Med. 2017; 49(9):e373. PMC: 5628280. DOI: 10.1038/emm.2017.172. View

Rojas-Martinez A, Manzanera A, Sukin S, Esteban-Maria J, Gonzalez-Guerrero J, Gomez-Guerra L . Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. Cancer Gene Ther. 2013; 20(11):642-9. PMC: 3842423. DOI: 10.1038/cgt.2013.56. View

Mayes J, Mouraviev V, Sun L, Tsivian M, Madden J, Polascik T . Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer?. Urol Oncol. 2009; 29(2):166-70. DOI: 10.1016/j.urolonc.2009.03.011. View

Nevedomskaya E, Baumgart S, Haendler B . Recent Advances in Prostate Cancer Treatment and Drug Discovery. Int J Mol Sci. 2018; 19(5). PMC: 5983695. DOI: 10.3390/ijms19051359. View

10.

Pernar C, Ebot E, Wilson K, Mucci L . The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med. 2018; 8(12). PMC: 6280714. DOI: 10.1101/cshperspect.a030361. View

11.

Salinas C, Tsodikov A, Ishak-Howard M, Cooney K . Prostate cancer in young men: an important clinical entity. Nat Rev Urol. 2014; 11(6):317-23. PMC: 4191828. DOI: 10.1038/nrurol.2014.91. View

12.

Ajith T . Strategies used in the clinical trials of gene therapy for cancer. J Exp Ther Oncol. 2015; 11(1):33-9. View

13.

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V . EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2010; 59(1):61-71. DOI: 10.1016/j.eururo.2010.10.039. View

14.

Gillessen S, Attard G, Beer T, Beltran H, Bossi A, Bristow R . Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2017; 73(2):178-211. DOI: 10.1016/j.eururo.2017.06.002. View

15.

Gurwith M, Lock M, Taylor E, Ishioka G, Alexander J, Mayall T . Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis. 2013; 13(3):238-50. PMC: 3576519. DOI: 10.1016/S1473-3099(12)70345-6. View

16.

Baden L, Walsh S, Seaman M, Johnson J, Tucker R, Kleinjan J . First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis. 2014; 210(7):1052-61. PMC: 4168302. DOI: 10.1093/infdis/jiu217. View

17.

Gangi A, Zager J . The safety of talimogene laherparepvec for the treatment of advanced melanoma. Expert Opin Drug Saf. 2016; 16(2):265-269. DOI: 10.1080/14740338.2017.1274729. View

18.

Brackett C, Kojouharov B, Veith J, Greene K, Burdelya L, Gollnick S . Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Proc Natl Acad Sci U S A. 2016; 113(7):E874-83. PMC: 4763744. DOI: 10.1073/pnas.1521359113. View

19.

Paulis G . Inflammatory mechanisms and oxidative stress in prostatitis: the possible role of antioxidant therapy. Res Rep Urol. 2018; 10:75-87. PMC: 6149977. DOI: 10.2147/RRU.S170400. View

20.

Reetz J, Genz B, Meier C, Kowtharapu B, Timm F, Vollmar B . Development of Adenoviral Delivery Systems to Target Hepatic Stellate Cells In Vivo. PLoS One. 2013; 8(6):e67091. PMC: 3688967. DOI: 10.1371/journal.pone.0067091. View